Comparative Outcomes in Pregnant Patients With Rheumatoid Arthritis Treated With and Without Tumour Necrosis Factor Inhibitors: A Systematic Review and Meta-Analysis. (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1846; Pres time: Nov 9, 2026; 08:30 AM - 08:45 AM; Location: W304 A-H; In Person; "The most frequently used TNFi were adalimumab, certolizumab, and etanercept. Infliximab and golimumab were administered only to a minority of patients in 2 studies... To our knowledge, this is the first meta-analysis evaluating outcomes in pregnant patients exclusively with RA, treated with or without anti-TNF inhibitors. Amongst patients with RA, TNFi use in pregnancy does not appear to be associated with congenital anomalies, SGA, or preterm birth. This could help inform patient counselling around continuation of TNFi in the prenatal period in this patient population."
Retrospective data • Review • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Small for Gestational Age
|
|
Eagan Peters1; Kunal Kolhatkar1; Ivan Ntale1; Dharini Mahendira2
|